PSA≥100 ng/ml患者的临床病程:靶向前列腺特异抗原筛查潜在人群的启示
该回顾性研究分析了2004至2011年间在Grady纪念医院就诊的204例初始PSA≥100 ng/ml患者中随机选取的100例,旨在描述其临床特征并识别靶向PSA筛查的潜在人群。结果显示81%已有转移性疾病,94%Gleason评分≥7,中位PSA为405.5 ng/ml,中位至死亡时间17.8个月,多数为非洲裔美国人且社会经济地位较低。作者认为统一缺乏前列腺癌筛查可能使更多高危男性面临类似结局,需讨论对高危脆弱患者进行靶向PSA筛查。
要点
- PSA≥100 ng/ml就诊者中81%已转移,94%Gleason≥7,中位PSA 405.5 ng/ml。
- 仅23%新诊断患者曾接受过筛查,9%曾活检,提示筛查缺失。
- 多数患者为非洲裔美国人、社会经济地位低,中位至死亡17.8个月。
核心结论
- 在安全网医院以PSA≥100 ng/ml就诊的男性中,多数为非洲裔美国人、社会经济地位较低且已有转移性疾病。
- 统一缺乏前列腺癌筛查可能使更多高危男性暴露于类似不良结局,需讨论对高危脆弱患者进行靶向PSA筛查。
研究设计与样本
- 回顾性研究,从2004至2011年Grady纪念医院204例初始PSA≥100 ng/ml患者中随机选取100例进行分析。
- 通过肿瘤登记处及电子病历和旧纸质病历获取人口学、疾病特征和生存状态,纸质病历缺失数据在分析中排除。
主要发现
- 65例为就诊时新诊断前列腺癌,35例为既往诊断。
- 就诊时中位PSA为405.5 ng/ml(最小值100,最大值7805),81%有转移性疾病,94%Gleason评分≥7。
- 中位癌症前列腺风险评估评分为8,就诊时中位年龄67.4岁(最小值40.8,最大值90.6)。
- 仅1%有HIV,19%有糖尿病,13%有慢性肾脏病;65例新诊断患者中仅23%曾接受过筛查,9%曾活检。
临床怎么用
- 对高危脆弱人群(如社会经济地位较低、非洲裔美国人)应考虑靶向PSA筛查,以避免晚期转移性疾病。
- 临床接诊PSA≥100 ng/ml患者时应评估转移性疾病和高级别Gleason评分,并关注极差生存。
局限性
- 回顾性研究,部分纸质病历数据缺失被排除分析。
- 样本来自单一安全网医院,随机选取100例,可能存在选择偏倚。
- 未报告筛查史与结局关联的统计检验或混杂因素调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize men presenting to a tertiary care safety-net hospital with prostate-specific antigen (PSA) values ≥100 ng/mL and to identify a potential population for targeted PSA screening. MATERIALS AND METHODS: Retrospective review of 100 randomly selected patients of a total of 204 who presented to Grady Memorial Hospital from 2004 to 2011 with initial PSA ≥100 ng/mL was performed. Demographics, disease characteristics, and survival status were obtained via the Tumor Registry and a combination of electronic medical records and older paper charts, with missing data from paper charts excluded on analyses. RESULTS: Sixty-five patients were newly diagnosed with prostate cancer on presentation and 35 were previously diagnosed. Median PSA at presentation was 405.5 ng/mL (minimum, 100 and maximum, 7805), 81% had metastatic disease, and 94% had Gleason ≥7. Median Cancer of the Prostate Risk Assessment score was 8. Median age at presentation was 67.4 years (minimum, 40.8 and maximum, 90.6). Eighty-nine percent of patients were African American, 24% lived alone, 12% were homeless or incarcerated, 51% were insured by Medicare or Medicaid, and 47% were uninsured. Only 1% had human immunodeficiency virus, 19% had diabetes, and 13% had chronic kidney disease. Of the 65 newly diagnosed patients, only 23% had ever been screened and 9% were previously biopsied. Median time from presentation to death was 17.8 months (minimum, 0.16 and maximum, 107.1). CONCLUSION: Among men presenting with PSA ≥100 ng/ml at a safety-net hospital, the majority were African American, of lower socioeconomic status, and had metastatic disease. Uniform absence of prostate cancer screening may expose greater numbers of at-risk men to similar outcomes. Discussion is needed regarding targeted PSA screening in higher risk, vulnerable patients.
引用
- Leung AK, Hugar L, Patil D, et al. The Clinical Course of Patients With Prostate-Specific Antigen ≥100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening. Urology. 2018. PMID: 29656066. doi:10.1016/j.urology.2018.01.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。